

Mikael Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4303726/publications.pdf>

Version: 2024-02-01

46
papers

1,583
citations

430442

18
h-index

315357

38
g-index

51
all docs

51
docs citations

51
times ranked

1467
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. <i>Journal of Neuroinflammation</i> , 2022, 19, 62.	3.1	30
2	Reliability of mobile video-oculography in multiple sclerosis patients using an iPad: A prospective validation study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 64, 103944.	0.9	3
3	BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1556-1563.	1.4	9
4	Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. <i>Journal of Neuroradiology</i> , 2021, 48, 28-36.	0.6	24
5	Digital biomarkers can highlight subtle clinical differences in radiologically isolated syndrome compared to healthy controls. <i>Journal of Neurology</i> , 2021, 268, 1316-1322.	1.8	5
6	Alexithymia in multiple sclerosis: Clinical and radiological correlations. <i>Revue Neurologique</i> , 2021, 177, 302-311.	0.6	7
7	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. <i>Annals of Neurology</i> , 2021, 89, 30-41.	2.8	123
8	Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. <i>Journal of Neuroradiology</i> , 2021, 48, 170-175.	0.6	4
9	The long-term outcome of MOGAD: An observational national cohort study of 61 patients. <i>European Journal of Neurology</i> , 2021, 28, 1659-1664.	1.7	26
10	Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis. <i>Neurotherapeutics</i> , 2021, 18, 938-948.	2.1	9
11	How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103076.	0.9	13
12	A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2025-2037.	1.7	20
13	Should we still only rely on EDSS to evaluate disability in multiple sclerosis patients? A study of inter and intra rater reliability. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103144.	0.9	10
14	MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103164.	0.9	6
15	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 936-944.	1.4	37
16	Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment. <i>Neurology and Therapy</i> , 2020, 9, 599-604.	1.4	7
17	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	3.7	24
18	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251.	0.9	110

#	ARTICLE	IF	CITATIONS
19	Radiologically Isolated Syndrome: <sc>10â€¥ear</sc> Risk Estimate of a Clinical Event. <i>Annals of Neurology</i> , 2020, 88, 407-417.	2.8	95
20	Thalamic atrophy correlates with dysfunctional impulsivity in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102374.	0.9	4
21	Video-oculography in multiple sclerosis: Links between oculomotor disorders and brain magnetic resonance imaging (MRI). <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101969.	0.9	8
22	Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies. <i>Journal of Neuroinflammation</i> , 2020, 17, 128.	3.1	13
23	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 134.	3.1	115
24	Impact of executive dysfunction on naming ability in multiple sclerosis. <i>Revue Neurologique</i> , 2019, 175, 552-559.	0.6	4
25	Immunoglobulin G4-related hypertrophic pachymeningitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e568.	3.1	41
26	Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions. <i>Journal of Neurology</i> , 2019, 266, 1743-1755.	1.8	9
27	Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 109-116.	0.9	9
28	De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine. <i>Multiple Sclerosis Journal</i> , 2019, 25, 618-621.	1.4	4
29	Connected health and multiple sclerosis. <i>Revue Neurologique</i> , 2018, 174, 480-485.	0.6	6
30	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. <i>Neurology</i> , 2018, 90, e1858-e1869.	1.5	401
31	Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders. <i>Neurology and Therapy</i> , 2018, 7, 373-383.	1.4	31
32	Monitoring CD27 + memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study. <i>Journal of the Neurological Sciences</i> , 2017, 373, 335-338.	0.3	58
33	Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year. <i>Journal of the Neurological Sciences</i> , 2017, 382, 73-78.	0.3	4
34	A Case Report of Solitary Sclerosis: This is Really Multiple Sclerosis. <i>Neurology and Therapy</i> , 2017, 6, 259-263.	1.4	12
35	Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 161-163.	0.9	3
36	Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2017, 12, e0168834.	1.1	25

#	ARTICLE	IF	CITATIONS
37	False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1231-1234.	1.4	13
38	Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders. <i>Journal of the Neurological Sciences</i> , 2016, 368, 334-336.	0.3	17
39	Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis. <i>Journal of Neuroimmunology</i> , 2016, 298, 79-81.	1.1	42
40	Solitary sclerosis: Experience from three French tertiary care centres. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1216-1216.	1.4	11
41	A Prospective Study of Patients with Brain MRI Showing Incidental T2 Hyperintensities Addressed as Multiple Sclerosis: a Lot of Work to do Before Treating. <i>Neurology and Therapy</i> , 2014, 3, 123-132.	1.4	22
42	The HV3 Score: A New Simple Tool to Suspect Cognitive Impairment in Multiple Sclerosis in Clinical Practice. <i>Neurology and Therapy</i> , 2014, 3, 113-122.	1.4	6
43	Switching From Natalizumab to Fingolimod in Multiple Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 436.	4.5	133
44	Moving to Fingolimod From Natalizumab in Multiple Sclerosis—Reply. <i>JAMA Neurology</i> , 2014, 71, 925.	4.5	2
45	Endermology: A treatment for injection-induced lipoatrophy in multiple sclerosis patients treated with sub cutaneous glatiramer acetate. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 721-724.	0.6	7
46	RECURRENT PERICARDITIS DUE TO NATALIZUMAB TREATMENT. <i>Neurology</i> , 2009, 72, 1616-1617.	1.5	5